SecBot SecBot
8-K ·Filed Nov 12, 2026

PROF

Profound Medical Corp.
NEUTRAL
Impact 3/10
Horizonweeks Processed4d 16h ago SEC0001104659-26-125909
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor the January 15, 2027 transition date for any strategic shifts under new CEO Richard Fabian, who comes from an ultrasound imaging background. The CFO appointment removes interim status uncertainty. No financial guidance or operational changes were announced.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$7.44
T+0 close · Nov 12, 2026 · via day close
Latest settled
−0.27%
T+1 · $7.42
Vs SPY
+0.09%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $7.44entry
  2. T+1 · 4d ago −0.27%α +0.09% · $7.42
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Profound Medical Corp. disclosed a leadership transition: CEO Arun Menawat will become Executive Chairman effective January 15, 2027, with President Richard Fabian appointed as the new CEO. The company also appointed Matthew Sobczyk as permanent CFO (he had been interim CFO since August 2026) and replaced departing director Cynthia Lavoie with Jason Mills. These are planned succession moves with no reported disagreements or red flags.

Key Facts

  • CEO Arun Menawat steps down as CEO effective January 15, 2027, becomes Executive Chairman with $225K annual cash and $375K annual stock award
  • Richard Fabian, age 59, appointed President and CEO effective January 15, 2027; joined as President on September 1, 2026
  • Matthew Sobczyk appointed permanent CFO effective November 5, 2026; had served as interim CFO since August 14, 2026
  • Director Cynthia Lavoie resigned effective November 5, 2026; no disagreement cited
  • Jason Mills appointed to fill board vacancy
  • Non-employee director compensation policy amended effective January 1, 2027: annual cash retainer $55,000, annual equity award $110,000

Financial Impact

No material financial impact disclosed; executive compensation changes are routine for a CEO transition

Risk Factors

  • CEO transition could signal a strategic pivot given Fabian's background in point-of-care ultrasound rather than Profound's core therapeutic ultrasound business
  • No financial data or guidance provided in this filing to assess business trajectory

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
80% bullish (5 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-125909
Document: 0001104659-26-125909-index-headers.html0001104659-26-125909
Document: 0001104659-26-125909-index.html0001104659-26-125909
Document: 0001104659-26-125909.txt0001104659-26-125909

Track record

22 reports on PROF

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +25.61% at T+60 after the Mar 5, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 3/10 Viewing Entry $7.44 Now $7.34 −1.34% settles Dec 11
  2. Nov 9, 20267d ago 8-K Neutral 2/10 Entry $7.34 Now $7.34 +0.00% settles Dec 8
  3. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.21 Now $7.34 −1.80% settles Dec 7
  4. Nov 3, 202613d ago 8-K Neutral 4/10 Entry $7.16 Now $7.34 +2.51% settles Dec 3
  5. Oct 30, 202617d ago Press Release Neutral 4/10 Entry $6.57 Now $7.34 +11.72% settles Nov 30
  6. Oct 22, 202625d ago 8-K Neutral 2/10 Entry $5.56 Now $7.34 +32.01% settles Nov 20
  7. Oct 14, 20264w ago 8-K Neutral 3/10 Entry $6.62 to $7.68 Now $7.34 +10.88% ▲ +16.01% +18.57% vs SPY
  8. Oct 9, 20265w ago 8-K Neutral 3/10 Entry $6.90 to $7.01 Now $7.34 +6.38% ▲ +1.59% +7.15% vs SPY
  9. Oct 7, 20265w ago 8-K Bullish 7/10 Entry $6.91 to $7.16 Now $7.34 +6.22% ▲ +3.62% +8.91% vs SPY
  10. Sep 3, 202610w ago 8-K Neutral 2/10 Entry $6.89 to $6.03 Now $7.34 +6.53% ▼ −12.48% −13.08% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 9h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026